Ions, equations and electrons: The evolving role of computer simulations in cardiac electrophysiology safety evaluations

British Journal of Pharmacology

Volumn 167, Issue 5, 2012, Pages 929-931

  Gintant, Gary ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

automated patch clamp; cardiac repolarization; computer modelling; hERG; IKr; ion channels; pro arrhythmia; QT prolongation; simulations; Torsades de Pointes

Indexed keywords

CALCIUM CHANNEL L TYPE; DELAYED RECTIFIER POTASSIUM CHANNEL; FLUOXETINE; MOXIFLOXACIN; VERAPAMIL;

AUTOMATION; CHANNEL GATING; COMPUTER SIMULATION; COST MINIMIZATION ANALYSIS; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; GOLD STANDARD; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HEART REPOLARIZATION; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PATCH CLAMP; PHARMACODYNAMICS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SODIUM CURRENT; T WAVE; TORSADE DES POINTES;

ALGORITHMS; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; ELECTRONS; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART; HUMANS; IONS; MODELS, CARDIOVASCULAR; PHARMACEUTICAL PREPARATIONS;

EID: 84867298944     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02096.x     Document Type: Review

References (10)

1. Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, et al,. (1996). Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther 276: 637-646. (Pubitemid 126660502)
2. Darpo B, (2010). The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 159: 49-57.
3. Fermini B, Fossa AA, (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2: 439-447. (Pubitemid 37361725)
4. Gintant G, (2011). An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129: 109-119.
5. ICH S7B The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Safety/S7B/Step4/S7B-Guideline.pdf.
6. Mirams G, Davies M, Cui Y, Kohl P, Noble D, (2012). Application of cardiac electrophysiology simulations to proarrhythmic safety testing. Br J Pharm 167: 932-945.
7. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, et al,. (2011). Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res 91: 53-61.
8. O'Hara T, Rudy Y, (2012). Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. Am J Physiol Heart Circ Physiol 302: H1023-H1030.
9. Oros A, Houtman MJ, Neco P, Gomez AM, Rajamani S, Oosterhoff P, et al,. (2010). Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action. Br J Pharmacol 161: 162-175.
10. Sugiyama A, (2008). Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced Torsades de Pointes in patients with remodeled hearts. Br J Pharmacol 154: 1528-1537.